BioLife Solutions (NASDAQ:BLFS) Downgraded by BidaskClub

Share on StockTwits

BidaskClub lowered shares of BioLife Solutions (NASDAQ:BLFS) from a hold rating to a sell rating in a research report released on Saturday, BidAskClub reports.

A number of other research analysts have also commented on the stock. ValuEngine raised shares of XCel Brands from a sell rating to a hold rating in a research report on Tuesday, July 9th. Zacks Investment Research lowered shares of ExlService from a hold rating to a sell rating in a research report on Wednesday, July 10th. Northland Securities upped their price objective on shares of Paycom Software from $215.00 to $275.00 and gave the company an outperform rating in a research report on Tuesday, July 9th. Finally, Maxim Group set a $24.00 price objective on shares of BioLife Solutions and gave the company a buy rating in a research report on Wednesday, May 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $17.80.

Shares of BLFS opened at $16.19 on Friday. The company’s 50-day moving average is $17.18. The firm has a market capitalization of $314.34 million, a price-to-earnings ratio of 115.64 and a beta of 1.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99. BioLife Solutions has a 52 week low of $9.15 and a 52 week high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.03. The business had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.67 million. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. Equities research analysts predict that BioLife Solutions will post 0.12 earnings per share for the current year.

In related news, CFO Greef Roderick De sold 10,000 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $16.53, for a total value of $165,300.00. Following the completion of the transaction, the chief financial officer now owns 40,359 shares of the company’s stock, valued at $667,134.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP James Mathers sold 2,500 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $17.15, for a total transaction of $42,875.00. Following the completion of the transaction, the vice president now directly owns 19,884 shares of the company’s stock, valued at approximately $341,010.60. The disclosure for this sale can be found here. Insiders sold 191,818 shares of company stock valued at $3,396,012 in the last three months. Company insiders own 27.00% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp raised its stake in BioLife Solutions by 36.1% during the 4th quarter. Bank of New York Mellon Corp now owns 64,930 shares of the medical equipment provider’s stock valued at $781,000 after purchasing an additional 17,209 shares during the period. GSA Capital Partners LLP raised its stake in BioLife Solutions by 21.1% during the 4th quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,400 shares during the period. Northern Trust Corp raised its stake in BioLife Solutions by 19.2% during the 4th quarter. Northern Trust Corp now owns 49,729 shares of the medical equipment provider’s stock valued at $598,000 after purchasing an additional 8,003 shares during the period. Geode Capital Management LLC raised its stake in BioLife Solutions by 34.1% during the 4th quarter. Geode Capital Management LLC now owns 83,588 shares of the medical equipment provider’s stock valued at $1,005,000 after purchasing an additional 21,267 shares during the period. Finally, Barclays PLC raised its stake in BioLife Solutions by 18,125.0% during the 4th quarter. Barclays PLC now owns 72,900 shares of the medical equipment provider’s stock valued at $877,000 after purchasing an additional 72,500 shares during the period. 45.79% of the stock is currently owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Read More: What is Call Option Volume?

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine
Unum Therapeutics  Price Target Lowered to $13.00 at Wedbush
Unum Therapeutics Price Target Lowered to $13.00 at Wedbush
Zendesk  Research Coverage Started at Compass Point
Zendesk Research Coverage Started at Compass Point
Afya  Coverage Initiated at Bank of America
Afya Coverage Initiated at Bank of America
Telefonica  Downgraded to “Neutral” at Bank of America
Telefonica Downgraded to “Neutral” at Bank of America


 
© 2006-2019 Zolmax.